Lipostat Indications/Uses

Dyslipidemia: Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated total cholesterol, LDL-C, apo B and triglyceride and to increase HDL-cholesterol in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial hypercholesterolemia), combined (mixed) hyperlipidemia (Fredrickson Type IIa and IIb), elevated serum triglyceride levels (Fredrickson Type IV) and for patients with dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. In addition, Atorvastatin is indicated to reduce total cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia.
In pediatric patients (10-17 years of age), Atorvastatin is indicated as an adjunct to diet to reduce total cholesterol, LDL-C and apo B levels in boys and post-menarchal girls, 10-17 years of age with heterozygous familial hypercholesterolemia with these following findings: LDL-C remains ≥ 190 mg/dL or; LDL-C ≥ 160 mg/dL with positive family history of premature CVD or; LDL-C  160 mg/dL with two or more other CVD risk factors are the present in the pediatric patient ≥ 160 mg/dL with two or more other CVD risk factors are the present in the pediatric patient.
Prevention of cardiovascular complications: In patients without clinically evident cardiovascular disease (CVD), and with or without dyslipidemia, but with multiple risk factors for coronary heart disease (CHD) such as smoking, hypertension, low HDL-cholesterol, a family history of early CHD or diabetes.
Atorvastatin is indicated to: Reduce the risk of fatal CHD and non-fatal myocardial infarction (MI); Reduce the risk of stroke; Reduce the risk of revascularization procedures and angina pectoris.
In patients with clinically evident CHD, Atorvastatin is indicated to: Reduce the risk of non-fatal MI; Reduce the risk of fatal and non-fatal stroke; Reduce the risk of revascularization procedures; Reduce the risk of hospitalization for congestive heart failure (CHF); Reduce the risk of angina.
Chronic kidney disease (CKD): In patients with diabetes with moderately decreased estimated glomerular filtration rate (eGFR), Atorvastatin is indicated to reduce the risk for CVD.
In patients with clinically evident CHD and CKD not requiring dialysis, Atorvastatin is indicated to reduce the risk of major cardiovascular events including stroke.
In patients with clinically evident CHD and/or diabetes with microalbuminuria, Atorvastatin is indicated to reduce the rate of GFR decline and progression of CKD.